Identify the influences of systemic lupus erythematosus on acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura using comprehensive bioinformatics analysis
Restricted accessResearch articleFirst published online November, 2023
Identify the influences of systemic lupus erythematosus on acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura using comprehensive bioinformatics analysis
The association between acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura (aTTP) and systemic lupus erythematosus (SLE) has been studied; however, the underlying molecular causes remain poorly understood. This research aimed to employ bioinformatics approaches to elucidate potential molecular mechanisms contributing to the pathogenesis of SLE and aTTP.
Material and methods
The Gene Expression Omnibus (GEO) database yielded GSE121239 and GSE36418 to get mutual different expression genes (DEGs). Subsequently, DEGs were subjected to process Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Then, the DEGs were used for protein–protein interaction (PPI) analysis and screened for hub genes and drugs by the DGIDB drug database.
Results
A total of 87 DEGs between the SLE and TTP datasets were identified. In the GO and KEGG analyses, DEGs were mainly enriched in the “regulation of transcription by RNA polymerase II” and “signaling pathways regulating pluripotency of stem cells.” After a PPI analysis, three hub genes (BMPR2, SMAD5, and ATF2) were identified. Finally, two drugs targeted to ATF2 were predicted by the DGIDB drug database.
Conclusions
Three core genes were linked to the molecular pathogenesis of SLE and aTTP, and two drugs may be viable treatments for both diseases.
ZhengXL. The standard of care for immune thrombotic thrombocytopenic purpura today. J Thromb Haemost2021; 19: 1864–1871.
2.
Kremer HovingaJAVeselySKTerrellDR, et al.Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood2010; 115, 1500–1511.
3.
FurlanMLämmleB. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol2001; 14: 437–454.
4.
CoppoPBengoufaDVeyradierARéseau d'Etude des Microangiopathies Thrombotiques de l'Adulte, et al.. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltim)2004; 83: 233–244.
5.
GeorgeJNVeselySKJamesJA. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J2007; 100: 512–514.
6.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
7.
PetriMFuWRangerA, et al.Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. BMC Med Genomics2019; 12: 4.
8.
EdgarCETerrellDRVeselySK, et al.Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura. PLoS One2015; 10: e0117614.
9.
ShermanBTHaoMQiuJ, et al.DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res2022; 50: W216–W221.
10.
SzklarczykDGableALNastouKC, et al.The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res2021; 49: D605–D612.
11.
Castro-MondragonJARiudavets-PuigRRauluseviciuteI, et al.JASPAR 2022: the 9th release of the open-access database of transcription factor binding profiles. Nucleic Acids Res2022; 50: D165–D173.
12.
FreshourSLKiwalaSCottoKC, et al.Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res2021; 49: D1144–D1151.
13.
SatohMKuwanaMOgasawaraT, et al.Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients. J Immunol1994; 153: 5838–5848.
14.
SunWYanSYangC, et al.Mesenchymal stem cells-derived exosomes ameliorate lupus by inducing M2 macrophage polarization and regulatory T cell expansion in MRL/lpr mice. Immunol Invest2022; 51: 1785–1803.
15.
DevendranAKarSBaileyR, et al.The role of Bone Morphogenetic Protein Receptor Type 2 (BMPR2) and the prospects of utilizing Induced Pluripotent Stem Cells (iPSCs) in pulmonary arterial hypertension disease modeling. Cells2022; 11.
16.
CuthbertsonIMorrellNWCarusoP. BMPR2 mutation and metabolic reprogramming in pulmonary arterial hypertension. Circ Res2023; 132: 109–126.
17.
XingYZhaoJZhouM, et al.The LPS induced pyroptosis exacerbates BMPR2 signaling deficiency to potentiate SLE-PAH. FASEB J2021; 35: e22044.
18.
LiuBMaoN. Smad5: signaling roles in hematopoiesis and osteogenesis. Int J Biochem Cell Biol2004; 36: 766–770.
19.
OrlowskiJ. SMAD5 signaling: more than meets the nuclei. Cell Res2017; 27: 1075–1076.
20.
LiuYMaZHuangZ, et al.MiR-122-5p promotes peritoneal fibrosis in a rat model of peritoneal dialysis by targeting Smad5 to activate Wnt/β-catenin pathway. Ren Fail2022; 44: 191–203.
21.
ZhangX-YLiH-NChenF, et al.Icariin regulates miR-23a-3p-mediated osteogenic differentiation of BMSCs via BMP-2/Smad5/Runx2 and WNT/β-catenin pathways in osteonecrosis of the femoral head. Saudi Pharm J2021; 29: 1405–1415.
22.
LewisMJMcAndrewMBWheelerC, et al.Autoantibodies targeting TLR and SMAD pathways define new subgroups in systemic lupus erythematosus. J Autoimmun2018; 91, 1–12.
23.
WatsonGRonaiZALauE. ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease. Pharmacol Res2017; 119: 347–357.
24.
XuXLiYWuY, et al.Increased ATF2 expression predicts poor prognosis and inhibits sorafenib-induced ferroptosis in gastric cancer. Redox Biol2023; 59: 102564.
25.
BhoumikARonaiZ. ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities. Cell Cycle2008; 7: 2341–2345.
RockGAShumakKHBuskardNA, et al.Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med1991; 325: 393–397.
28.
KellyESutcliffeKCavalloD, et al.The anomalous pharmacology of fentanyl. Br J Pharmacol2023; 180: 797–812.
29.
DeshpandeASRamireddySSudandiradossC, et al.Streptozocin; a GLUT2 binding drug, interacts with human serum albumin at loci h6DOM3-h7DOM3. Int J Biol Macromol2019; 128: 923–933.
30.
KimJYLeeSHSongEH, et al.A critical role of STAT1 in streptozotocin-induced diabetic liver injury in mice: controlled by ATF3. Cell Signal2009; 21: 1758–1767.
